Last updated: August 8, 2025
Introduction
China Patent CN107501110—filed and granted within the Chinese intellectual property system—represents a significant development in the realm of pharmaceutical innovations. As the Chinese pharmaceutical market expands, understanding the specificities of patent CN107501110 is crucial for stakeholders, including pharmaceutical companies, patent attorneys, and R&D entities. This analysis dissects the patent’s scope, claims, and its positioning within the broader patent landscape, providing strategic insights for organizations engaging with this invention.
Patent Overview and Context
CN107501110 was granted in 2018, reflecting China's increasing focus on safeguarding biotech and drug innovations. Its classification aligns with therapeutic agents, likely constructioned to cover a specific drug compound, formulation, or application, although the precise subject matter requires detailed examination of the claims.
The patent operates within China's patent system governed by the Chinese Patent Law, which offers utility and inventive step protections, especially in the pharmaceutical sphere. It aligns with China's strategic push to bolster indigenous innovation and provide robust rights for pharmaceutical inventions to foster domestic development and foreign investment.
Scope of the Patent: An Overview
Patent Family and Related Technology
While detailed family data is not explicitly available here, patents like CN107501110 are often part of broader family portfolios including equivalents in jurisdictions such as WIPO, US, and EU. The core invention likely pertains to a novel compound, a method of preparation, or a therapeutic use related to a pharmaceutical compound.
Drafting and Claim Strategy
In Chinese pharmaceutical patents, the claims generally encompass:
- Compound claims: Covering chemical entities with specific structures.
- Use claims: Protecting specific therapeutic indications or methods.
- Formulation claims: Detailing pharmaceutical compositions with specific excipients or delivery systems.
- Method claims: Methodologies of synthesis or application.
Given the typical structure of similar patents, CN107501110 presumably emphasizes claims that maximize legal exclusivity, including multiple dependent claims that narrow the scope incrementally to reinforce enforceability.
Claims Analysis
1. Independent Claims
The core of the patent’s protection resides in the independent claims:
-
Novel Chemical Compound: Claims that specify the structure, stereochemistry, or derivatives of a unique molecule. The claims are likely anchored on a chemical structure that differs from prior art in substituents, stereoisomerism, or linkage.
-
Therapeutic Use or Method: Claims that articulate a specific medical application, such as treating certain cancers, inflammatory diseases, or other conditions, utilizing the compound.
-
Preparation Method: Claims that define synthetic routes, purification methods, or formulation techniques.
The specificity of these claims determines their strength:
- Overly broad claims risk being invalidated during examination or litigation due to prior art.
- Narrow claims, though more robust, limit market scope.
2. Dependent Claims and Their Role
Dependent claims specify particular embodiments:
- Specific substituents, stereochemistry, or formulations.
- Dosing regimens, administration routes, or combination therapies.
These further refine patent protection, creating a layered defense should infringement occur.
3. Claims Implications and Enforcement
While the protection scope depends on claim language, key points include:
- Chemical Structure Claims: Typically strong if novel and non-obvious.
- Use Claims: Enforceable for specific indications, but may face challenges based on prior uses or disclosures.
- Method Claims: Protect processes, but enforceability depends on jurisdiction and disclosure.
Patent Landscape Analysis in China
1. Competitive Landscape
China’s pharmaceutical patent environment is highly active:
- Domestic Innovation: Chinese firms, including Hua Medicine and Zai Lab, excel in biotech patents.
- International Players: Multinationals such as Pfizer and Novartis file extensive patent families covering new chemical entities and uses.
- Patent Thickets: Several overlapping patents exist for similar therapeutic classes, creating complex freedom-to-operate considerations.
Regarding CN107501110 specifically, its positioning within the landscape suggests a strategic attempt to carve out protection in a niche or novel chemical space, or specify innovative uses.
2. Prior Art and Patentability
The patent examiner would have scrutinized CN107501110 against prior art:
- Chemical prior art: Similar compounds, functional groups, or pharmacophores.
- Use prior art: Existing therapies targeting the same indication.
- Synthesis methods: Known routes may limit claims if too similar.
To overcome rejections, patentees often narrow claims or emphasize unexpected advantages, such as improved efficacy or reduced side effects.
3. Patent Term and Extension Potential
Patent protection typically lasts 20 years from filing, with possible extensions or supplementary protection certificates (SPCs) in certain cases. Given the 2018 filing date, the patent remains enforceable until 2038, barring any legal challenges.
Strategic Implications
- For Innovators: CN107501110 exemplifies the importance of precise claim drafting to balance broad coverage and validity.
- For Patent Holders: Proactive landscape monitoring ensures freedom-to-operate and helps identify potential infringement opportunities.
- For Filing Strategies: Applying for international patents in jurisdictions with similar standards, like USPTO or EPO, enhances global protection.
Key Takeaways
- The scope of CN107501110 is predominantly defined by specific chemical compounds, therapeutic uses, and synthesis methods, with claims structured to secure a broad yet defensible protection.
- Its claims likely include both structure-based and use-based protections, which are typical but must be carefully crafted to withstand prior art challenges.
- The patent landscape in China is highly competitive, with a dense field of pharmaceutical patents, underscoring the necessity for continuous monitoring and strategic claim amendments.
- Effective patent strategy in China involves detailed understanding of local patent laws, prior art nuances, and international filings to maximize exclusivity.
FAQs
1. What is the core innovation protected by CN107501110?
The patent primarily protects a novel chemical compound, its therapeutic uses, or specific synthetic methods. Exact details depend on the claim language, but generally, it covers a proprietary drug molecule or its application.
2. How broad are the claims typically in Chinese pharmaceutical patents like CN107501110?
Claims usually range from narrowly focused (specific compounds or methods) to broader structural or functional claims. Chinese patent practice encourages specific claims to strengthen validity but also includes broader claims to cover patentable equivalents.
3. Can CN107501110 be challenged or invalidated?
Yes. If prior art demonstrates the compound or use existed before the filing date, the patent could face invalidation. Chinese courts and patent officials evaluate novelty and inventive step rigorously.
4. How does the Chinese patent landscape affect patentability of similar drugs?
The dense patent landscape necessitates thorough prior art searches and strategic claim drafting to carve out non-infringing yet commercially valuable protection.
5. What are the key considerations for licensing or enforcement of CN107501110?
Understanding claim scope, prior art, and competitors’ portfolios is vital. Enforcement involves monitoring markets, verifying infringement, and navigating Chinese litigation procedures.
References
[1] Chinese Patent Office (SIPO). Patent CN107501110 Documentation and Public Records.
[2] China National Intellectual Property Administration (CNIPA). Patent Examination Guidelines.
[3] WIPO Patent Landscape Reports.
[4] China Pharmaceutical Patent Analysis Reports.
[5] Industry reports on Chinese biotech patent filing trends.
This analysis aims to guide stakeholders in understanding the strategic significance of China Patent CN107501110, enabling informed decision-making in patent prosecution, licensing, and litigation.
